Artificial intelligence and machine learning are reshaping how investors build and maintain portfolios. These tools bring ...

Two important architectures are Artificial Neural Networks and Long Short-Term Memory networks. LSTM networks are especially useful for financial applications because they are designed to work with ...

A deep learning framework enhances medical image recognition by optimizing RNN architectures with LSTM, GRU, multimodal fusion, and CNN ...

I put Gemini 3.0 and Grok 4.1 through 9 head-to-head prompts — from logic and creativity to humor and tone. Here's what ...

Artificial intelligence can already beat grandmasters at Go, draft legal briefs, and generate photorealistic images in ...

Interactive platforms like Codecademy and Dataquest.io let you learn and code right in your browser, making python online practice easy and accessible. For structured learning, Coursera and the ‘Think ...

Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...